MedPage Today on MSN

Non-Ablative Treatment for BPH/LUTS Achieves Rapid, Sustained Improvements

Results with Optilume consistent in clinical trials and real world, regardless of prostate ...
MedTech Intelligence

Prodeon Medical FDA 510(k) approved for the Urocross Expander System, a Non-Permanent Retrievable Implant for Treating Benign Prostatic Hyperplasia

The Urocross Expander System is designed to remodel the obstructing prostatic lobes during the six-month indwell time and is ...

Boston Scientific Corporation: Boston Scientific receives FDA clearance for the Asurys Fluid Management System

New technology designed to provide a single irrigation management system for ureteroscopy, cystoscopy, percutaneous nephrolithotomy (PCNL) and benign prostatic hyperplasia ...
Pharmabiz

Prodeon Medical’s Urocross Expander System receives US FDA 510(k) clearance for treating urinary symptoms associated with benign prostatic hyperplasia

Prodeon Medical’s Urocross Expander System receives US FDA 510(k) clearance for treating urinary symptoms associated with benign prostatic hyperplasia: Sunnyvale, California Thu ...
Cure Today

Blue Light Cystoscopy Reduces Recurrence in High-Risk Bladder Cancer

Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...